{"id":"rasagiline-mesylate-plus-mirapex","safety":{"commonSideEffects":[{"rate":null,"effect":"Dyskinesia"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hallucinations"},{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Orthostatic hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rasagiline is a selective MAO-B inhibitor that prevents the breakdown of dopamine, while Mirapex (pramipexole) is a dopamine D2/D3 receptor agonist that directly stimulates dopamine receptors. Together, they increase dopamine availability and receptor activation, providing complementary symptomatic relief in Parkinson's disease by addressing both dopamine preservation and receptor stimulation.","oneSentence":"This combination pairs a monoamine oxidase B inhibitor with a dopamine agonist to enhance dopaminergic signaling in the brain for Parkinson's disease management.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:37:04.337Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"}]},"trialDetails":[{"nctId":"NCT01968460","phase":"PHASE2, PHASE3","title":"Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease","status":"COMPLETED","sponsor":"Pharma Two B Ltd.","startDate":"2013-12","conditions":"Parkinson's Disease","enrollment":149},{"nctId":"NCT03329508","phase":"PHASE3","title":"A Phase 3 Study With P2B001 in Subjects With Early Parkinson's","status":"COMPLETED","sponsor":"Pharma Two B Ltd.","startDate":"2018-01-19","conditions":"Parkinson Disease, Early Parkinson's Disease","enrollment":544},{"nctId":"NCT01048229","phase":"PHASE4","title":"Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease","status":"TERMINATED","sponsor":"Qualissima","startDate":"2008-10","conditions":"Early-stage Parkinson's Disease","enrollment":112},{"nctId":"NCT00399477","phase":"PHASE4","title":"A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease","status":"COMPLETED","sponsor":"Teva Neuroscience, Inc.","startDate":"2006-10","conditions":"Parkinson's Disease","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rasagiline mesylate plus Mirapex","genericName":"Rasagiline mesylate plus Mirapex","companyName":"Teva Neuroscience, Inc.","companyId":"teva-neuroscience-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination pairs a monoamine oxidase B inhibitor with a dopamine agonist to enhance dopaminergic signaling in the brain for Parkinson's disease management. Used for Parkinson's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}